Literature DB >> 23397209

Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL).

Silvia Park1, Su Jin Lee, Kihyun Kim, Jun Ho Jang, Dong Hwan Kim, Kyu Hyung Lee, Je Hwan Lee, Jung Hee Lee, Dae Young Kim, Dae-Young Jang, Hawk Kim, Jae Hoo Park, Hun Mo Ryoo, Sung Hwa Bae, Min Kyung Kim, Myung Soo Hyun, Young Don Joo, Won Sik Lee, Sang Min Lee, Chul Won Jung.   

Abstract

The clinical outcomes of acute promyelocytic leukemia (APL) have improved greatly, but treatment failure still occurs. Identification of patients with poor prognosis is fundamental, and we propose a new clinical prognostic system (CBC-score) consisting of WBC, platelet count, and hemoglobin level. Between 1995 and 2009, 156 patients with APL from seven institutes in Korea were retrospectively reviewed. In the new CBC-score system, each of the following (WBC ≥ 10 × 109/L, platelet <40 × 109/L, hemoglobin <8.0 g/dL) was considered as a risk factor; the sum of each was designated as the CBC-score. With a median follow-up of 8.4 years, the complete remission (CR) rate was 81.4 % (127/156), while 24 (15.4 %) were considered as treatment failures due to early death (ED). The 5-year overall survival (OS), leukemia-free survival, and cumulative incidence of relapse were 73.8, 82.8, and 13.5 %, respectively. Compared to the individual CBC parameters, combined prognostic systems such as PETHEMA or CBC-score provided better prognostic stratification. Compared to PETHEMA stratification, the proposed prognostic CBC-score system showed better stratification of APL patients in terms of CR rates (p = 0.004), OS (p = 0.004), and ED (p = 0.008). This retrospective study suggests that the proposed CBC-score may provide better prognostic stratification of APL patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23397209     DOI: 10.1007/s12185-013-1276-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

Review 1.  Anemia of chronic disease.

Authors:  Guenter Weiss; Lawrence T Goodnough
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 2.  Acute promyelocytic leukemia: evolving therapeutic strategies.

Authors:  Martin S Tallman; Chadi Nabhan; James H Feusner; Jacob M Rowe
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Authors:  Miguel A Sanz; Pau Montesinos; Chelo Rayón; Alexandra Holowiecka; Javier de la Serna; Gustavo Milone; Elena de Lisa; Salut Brunet; Vicente Rubio; José M Ribera; Concha Rivas; Isabel Krsnik; Juan Bergua; José González; Joaquín Díaz-Mediavilla; Rafael Rojas; Félix Manso; Gert Ossenkoppele; José D González; Bob Lowenberg
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

4.  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

Authors:  M A Sanz; G Martín; C Rayón; J Esteve; M González; J Díaz-Mediavilla; P Bolufer; E Barragán; M J Terol; J D González; D Colomer; C Chillón; C Rivas; T Gómez; J M Ribera; R Bornstein; J Román; M J Calasanz; J Arias; C Alvarez; F Ramos; G Debén
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

Review 5.  Diagnosis and management of iron-deficiency anaemia.

Authors:  James D Cook
Journal:  Best Pract Res Clin Haematol       Date:  2005-06       Impact factor: 3.020

6.  Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.

Authors:  N Asou; K Adachi; J Tamura; A Kanamaru; S Kageyama; A Hiraoka; E Omoto; H Akiyama; K Tsubaki; K Saito; K Kuriyama; H Oh; K Kitano; S Miyawaki; K Takeyama; O Yamada; K Nishikawa; M Takahashi; S Matsuda; S Ohtake; H Suzushima; N Emi; R Ohno
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

Review 7.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

8.  Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.

Authors:  Alessandro Pulsoni; Livio Pagano; Francesco Lo Coco; Giuseppe Avvisati; Luca Mele; Eros Di Bona; Rosangela Invernizzi; Franco Leoni; Filippo Marmont; Alfonso Mele; Lorella Melillo; Anna Maria Nosari; Enrico Maria Pogliani; Marco Vignetti; Giuseppe Visani; Vittorina Zagonel; Giuseppe Leone; Franco Mandelli
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

Review 9.  Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.

Authors:  Andres Sirulnik; Ari Melnick; Arthur Zelent; Jonathan D Licht
Journal:  Best Pract Res Clin Haematol       Date:  2003-09       Impact factor: 3.020

10.  All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Authors:  Martin S Tallman; Janet W Andersen; Charles A Schiffer; Frederick R Appelbaum; James H Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

View more
  3 in total

1.  Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia.

Authors:  Giuseppina Loglisci; Clara Minotti; Alessandra Serrao; Matteo Molica; Laura Cicconi; Roberta Saracino; Massimo Breccia
Journal:  Int J Hematol       Date:  2013-09-15       Impact factor: 2.490

2.  Individualized Prediction Of Stroke-Associated Pneumonia For Patients With Acute Ischemic Stroke.

Authors:  Gui-Qian Huang; Yu-Ting Lin; Yue-Min Wu; Qian-Qian Cheng; Hao-Ran Cheng; Zhen Wang
Journal:  Clin Interv Aging       Date:  2019-11-07       Impact factor: 4.458

3.  Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia.

Authors:  Jingjing Wen; Fang Xu; Qiaolin Zhou; Lin Shi; Yiping Liu; Jing Yue; Ya Zhang; Xiaogong Liang
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.